Background {#section1-1534735415624138}
==========

Lung cancer (LC) is diagnosed in more than 221 000 patients in the United States annually.^[@bibr1-1534735415624138]^ Medical advances have improved survival for LC, but because of disease burden, preexisting illness, and the toxicities of therapy, patients with LC have a significant respiratory symptom burden.^[@bibr2-1534735415624138],[@bibr3-1534735415624138]^ Dyspnea is present in up to 87% of patients with LC and has a profound impact on quality of life and survival.^[@bibr4-1534735415624138][@bibr5-1534735415624138][@bibr6-1534735415624138][@bibr7-1534735415624138]-[@bibr8-1534735415624138]^ The existing literature is sparse on interventions to improve dyspnea for patients with LC.^[@bibr9-1534735415624138]^ Physicians also appear to treat the dyspnea associated with LC less aggressively than they do dyspnea associated with chronic lung disease.^[@bibr10-1534735415624138]^ Effective interventions for dyspnea are a clear area of need for patients with LC.

Acupuncture is a component of a 2500-year-old Eastern medical system and is used by more than 2 million adults annually in the United States. Multiple studies have shown acupuncture to be safe when administered by trained practitioners.^[@bibr11-1534735415624138][@bibr12-1534735415624138]-[@bibr13-1534735415624138]^ A recent systematic review has revealed significant efficacy of acupuncture for a variety of cancer-related symptoms.^[@bibr14-1534735415624138]^ Although the exact mechanism of action for acupuncture is not fully understood, recent animal and human studies have demonstrated an effect that is mediated in part by endogenous opioid release.^[@bibr15-1534735415624138],[@bibr16-1534735415624138]^ These molecules bind the same opioid receptors engaged by synthetic opioids currently used for dyspnea treatment. In addition, neuroimaging studies suggest that acupuncture stimulation may influence the limbic system,^[@bibr17-1534735415624138]^ a brain region whose activity is known to be modulated by dyspnea.^[@bibr7-1534735415624138]^ Endogenous opioid release and limbic system stimulation provide biological plausibility for the use of acupuncture as a treatment for dyspnea.

As with many other integrative modalities, the scarcity of properly designed and conducted randomized controlled trials is a major barrier to more widespread use.^[@bibr18-1534735415624138],[@bibr19-1534735415624138]^ A single randomized study has evaluated acupuncture for dyspnea, but significant issues limit interpretation of this trial. The amount of acupuncture administered was substandard, and the study combined acupuncture with acupressure.^[@bibr20-1534735415624138]^ To evaluate the potential role of traditional acupuncture for the treatment of dyspnea in LC in a formal manner, we performed a pilot study. The specific aims of this study were (1) to evaluate the feasibility of accruing patients with LC to a trial of acupuncture and (2) to estimate preliminary effect size and safety of the intervention.

Materials and Methods {#section2-1534735415624138}
=====================

Study Patient Population {#section3-1534735415624138}
------------------------

We recruited eligible patients from the thoracic oncology clinics at the Abramson Cancer Center of the University of Pennsylvania. Patients 18 years and older were eligible if they had a diagnosis of LC, a dyspnea severity score of at least 4 on a Numerical Rating Scale (NRS) from 0 to 10 (10 being *most severe shortness of breath imaginable*), an Eastern Cooperative Oncology Group Performance Status of 1 to 3 and could provide informed consent and complete study surveys in English. Key exclusion criteria included life expectancy of less than 12 weeks as assessed by the treating oncologist, an organic cause of dyspnea requiring immediate treatment (eg, pleural effusion, acute radiation pneumonitis as measured by treatment with steroids for less than 3 weeks, acutely progressive disease, or severe anemia), or a current bleeding disorder. Informed consent was obtained from all patients prior to participation. This study received approval from the institutional review board at the University of Pennsylvania.

Study Intervention {#section4-1534735415624138}
------------------

The acupuncture treatment regimen was semistandardized, which has been an effective approach in prior studies of acupuncture.^[@bibr21-1534735415624138]^ The acupuncture points were chosen based on a review of the literature and were further informed by a team of licensed acupuncturists, a palliative care physician, and an oncologist with knowledge of LC treatment. The primary acupuncture points were chosen to improve dyspnea, but additional points were presented as optional in the case of a particular symptom (see Supplemental Table 1 \[available at <http://ict.sagepub.com/supplemental>\] for acupuncture points used). The needles (25 or 40 mm and 0.25 gauge, Seirin, Seirin-America Inc, Weymouth, MA) were inserted until the patient reported a sensation of soreness (termed *De Qi*). Treatments occurred in 2 stages. Patients were first seated in a comfortable chair in the chemotherapy infusion suite to allow the placement of anterior needles. These needles remained in place for 15 to 20 minutes and were then removed. Patients were then placed face down in a massage chair for the placement of posterior needles. These needles were also kept in place for 15 to 20 minutes and then removed. No stimulation of the acupuncture needles was utilized. Patients received weekly treatments for 10 weeks and had a follow-up visit 4 weeks after the end of treatment. This dose of acupuncture has been effective in prior trials.^[@bibr22-1534735415624138]^ Two licensed acupuncturists, each with greater than 10 years of experience, administered the acupuncture.

Data Collection and Outcome Measurement {#section5-1534735415624138}
---------------------------------------

Patient-reported outcome instruments were utilized to obtain information on symptom severity. Patients completed surveys at baseline, at the end of treatment, and at a follow-up visit 4 weeks after treatment completion.

The primary outcome of the study was dyspnea severity in the past 7 days, as measured by a Dyspnea NRS. Scores on the NRS ranged from 0 (*no shortness of breath*) to 10 (*most severe shortness of breath imaginable*). NRSs have been used extensively in the measurement of dyspnea and are responsive to change.^[@bibr23-1534735415624138]^

Given the limitations of unidimensional measurement of a complex symptom such as dyspnea,^[@bibr23-1534735415624138]^ we also used a multidimensional instrument. The Cancer Dyspnea Scale (CDS) was originally written and validated in Japan to assess the effort, anxiety, and discomfort associated with dyspnea^[@bibr24-1534735415624138]^ and has since been validated in English.^[@bibr25-1534735415624138]^ The CDS is structured around 3 domains: sense of discomfort, sense of anxiety, and sense of effort. Scores range from 0 to 49, and a higher score indicates more severe dyspnea. The CDS is the only multidimensional dyspnea assessment tool that is validated in cancer patients, but it has never been used in a clinical trial. Thus, we did not know its sensitivity to change and chose to use the CDS as a secondary outcome measure.

Patients with LC often describe their dyspnea as a feeling of fatigue,^[@bibr26-1534735415624138]^ so we also measured fatigue with the Brief Fatigue Inventory (BFI).^[@bibr27-1534735415624138]^ The BFI is a validated instrument for the assessment of fatigue among patients with cancer. We also measured global quality of life using the Functional Assessment of Cancer Therapy--Lung version (FACT-L).^[@bibr28-1534735415624138]^ Each of these validated instruments was utilized at baseline, at the end of treatment, and at the follow-up visit.

To monitor objective findings related to dyspnea severity, we performed spirometry and lung volume measurements in the pulmonary function laboratory at the University of Pennsylvania at baseline and at the end of treatment. In addition, patients completed a 6-minute walk test, which has been validated as a prognostic marker in patients with dyspnea.^[@bibr29-1534735415624138]^

To define the patient's impression of their dyspnea improvement with acupuncture, we administered the Patient Global Impression of Change instrument^[@bibr30-1534735415624138]^ weekly throughout therapy.

Sample Size Calculation and Statistical Analysis {#section6-1534735415624138}
------------------------------------------------

All statistical analyses were performed in STATA (STATA v12.1, College Station, TX). For our primary outcome, we used a paired, 2-sided *t* test to compare the dyspnea severity as measured by NRS at baseline with the score at the end of treatment. Significance was defined at .05. Based on prior studies, the SD of a NRS measuring dyspnea among patients with LC is 2.1.^[@bibr23-1534735415624138]^ We hypothesized that if acupuncture could cause an effect size of 1 SD reduction in dyspnea, we would need 10 individuals to have 80% power to detect such difference, using a 2-sided significance level of .05. We chose a 12-subject sample size to account for an expected loss to follow-up rate of 15%.

To better characterize the effect of acupuncture among patients with LC, we performed a series of paired *t* tests to compare objective pulmonary measurements and symptom severity at the end of treatment and at the follow-up visit with baseline measurements. All tests were 2-sided, and a significance level of .05 was used. Given our small sample size, these evaluations should be regarded as exploratory.

Results {#section7-1534735415624138}
=======

Participant Characteristics {#section8-1534735415624138}
---------------------------

We screened 17 patients to identify the 12 patients who enrolled in our study (see [Figure 1](#fig1-1534735415624138){ref-type="fig"}). The median age of enrolled patients was 64.5 years, with a SD of 10 years, and 66.7% of patients were female. The racial breakdown of enrolled patients included 66.7% Caucasians, 25% African Americans, and 8.3% Asian Americans. Prior treatment included surgery (25%), radiation therapy (58.3%), and chemotherapy (75%); 33.3% of patients had recurrent/metastatic disease and were receiving active treatment (see [Table 1](#table1-1534735415624138){ref-type="table"}). Of note, all patients who received radiation therapy also received concurrent chemotherapy.

![CONSORT diagram.\
Abbreviations: PD, progressive disease.](10.1177_1534735415624138-fig1){#fig1-1534735415624138}

###### 

Patient Characteristics.

![](10.1177_1534735415624138-table1)

  Age, Median (SD)                                                         64.5 (10)
  ------------------------------------------------------------------------ ------------
  Gender                                                                   
   Female                                                                  8 (66.7%)
   Male                                                                    4 (33.3%)
  Race                                                                     
   Caucasian                                                               8 (66.7%)
   African American                                                        3 (25%)
   Asian                                                                   1 (8.3%)
  Smoking status                                                           
   Former smoker                                                           9 (75%)
   Never smoker                                                            3 (25%)
  Employment status                                                        
   Employed full time                                                      2 (16.7%)
   Not currently employed                                                  10 (83.3%)
  Marital status                                                           
   Married                                                                 9 (75%)
   Divorced                                                                2 (16.7%)
   Widowed                                                                 1 (8.3%)
  Initial cancer stage                                                     
   I                                                                       1 (8.3%)
   III                                                                     7 (58.3%)
   IV                                                                      4 (33.3%)
  Prior surgery                                                            
   Yes                                                                     3 (25%)
   No                                                                      9 (75%)
  Prior radiation^[a](#table-fn1-1534735415624138){ref-type="table-fn"}^   
   Yes                                                                     7 (58.3%)
   No                                                                      5 (41.7%)
  Prior chemotherapy                                                       
   Yes                                                                     9 (75%)
   No                                                                      3 (25%)
  Recurrent/Persistent disease                                             
   Yes                                                                     4 (33.3%)
   No                                                                      8 (66.7%)

All patients receiving radiation therapy received concurrent chemotherapy.

Feasibility and Safety {#section9-1534735415624138}
----------------------

In this study, 83.3% of patients were able to receive all scheduled acupuncture treatments, with only 2 patients unable to attend all sessions. One patient withdrew from the study because of a long commute to the center, and another had progression of LC while on the study and was unable to participate further because of illness. A third patient had progression of disease after the final acupuncture appointment and was unable to attend the follow-up visit. All patients who completed at least 1 acupuncture session were included in the final analysis.

Despite the use of chest wall acupuncture points in a population with a high incidence of emphysema, no patient experienced a pneumothorax. There were no attributable adverse events of grade 2 or higher seen in this study.

There were 3 possibly related or related adverse events noted during \>100 acupuncture sessions. There were 2 patients who experienced mild redness/bruising near a needle site, and 1 patient experienced a minor exacerbation of chronic back pain. All adverse events were mild and resolved without intervention.

Improvement in Dyspnea {#section10-1534735415624138}
----------------------

Mean dyspnea severity (SD) on the NRS was 6.3 (1.7) at baseline, 3.6 (1.9) at the end of treatment, and 3.2 (2.3) at follow-up. There was a statistically significant difference between both later time points and baseline (*P* = .003 and .008, respectively). There was a 49% reduction in dyspnea severity from baseline to follow-up. This was a clinically significant effect size, correlating with a Cohen's *d* of 1.49 at the end of treatment and 1.53 at the follow-up. Scores on the CDS also improved from 12.3 (6.8) at baseline to 7.1 (4.8) at the end of treatment and 6.3 (4.8) at follow-up. This was also a statistically significant difference (*P* = .04 for both comparisons). There was a numerical improvement in all subscales of the CDS at the end of treatment and at follow-up (see [Table 2](#table2-1534735415624138){ref-type="table"}). At the end of treatment, 60% of patients reported that their dyspnea was at least somewhat better, and at the follow-up visit, 77.8% of patients reported at least some improvement in dyspnea. No patient experienced worsening of dyspnea.

###### 

Symptom Scales.

![](10.1177_1534735415624138-table2)

  Symptom Scale                 Baseline Mean (SD)   EOT Mean (SD)                                                      *p* Value   FU Mean (SD)                                                       *p* Value
  ----------------------------- -------------------- ------------------------------------------------------------------ ----------- ------------------------------------------------------------------ -----------
  Dyspnea NRS                   6.3 (1.7)            3.6 (1.9)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .003        3.2 (2.3)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .008
  Cancer Dyspnea Scale--Total   12.3 (6.8)           7.1 (4.8)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .04         6.3 (4.8)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .04
   Sense of discomfort          3.8 (1.9)            2.5 (2.0)                                                          .08         2.1 (1.8)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .01
   Sense of anxiety             3.9 (2.9)            2.1 (2.0)                                                          .27         1.8 (1.8)                                                          .21
   Sense of effort              4.5 (3.2)            2.5 (2.1)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .03         2.4 (2.3)                                                          .10
  FACT-L                        72.4 (20)            94.4 (17)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .03         95.5 (13)                                                          .07
  BFI                           4.8 (2.4)            2.8 (2.1)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .05         3.6 (2.0)^[a](#table-fn2-1534735415624138){ref-type="table-fn"}^   .04

*P* value of \<.05 when compared with baseline.

Abbreviations: SD, standard deviation; EOT, end of treatment; FU, follow-up; NRS, Numerical Rating Scale; FACT-L, Functional Assessment of Cancer Therapy--Lung version; BFI, Brief Fatigue Inventory.

Improvement in Related Symptoms {#section11-1534735415624138}
-------------------------------

Overall, participants experienced an improvement in fatigue and global quality of life at the end of treatment. The effect on fatigue maintained statistical significance at the follow-up visit (see [Table 2](#table2-1534735415624138){ref-type="table"}). No statistically significant changes were seen in pulmonary function testing or in 6-Minute Walking Distance (see [Table 3](#table3-1534735415624138){ref-type="table"}).

###### 

Pulmonary Function Test Results.

![](10.1177_1534735415624138-table3)

  Variable                     Baseline Mean (SD)   EOT Mean (SD)    *p* Value
  ---------------------------- -------------------- ---------------- -----------
  FVC (L)                      2.0 (0.6)            2.1 (0.6)        .30
  FVC (percentage expected)    65.3 (14.4)          67.6 (15.9)      .15
  FEV1 actual (L)              1.4 (0.4)            1.5 (0.5)        .41
  FEV1 (percentage expected)   60.6 (14.3)          62.9 (15.5)      .19
  6MWD (feet)                  1017.8 (323.9)       1026.3 (341.4)   .89

Abbreviations: SD, standard deviation; EOT, end of treatment; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; 6MWD, 6-Minute Walking Distance.

Discussion {#section12-1534735415624138}
==========

Dyspnea is a distressing symptom that is highly prevalent among patients with LC^[@bibr4-1534735415624138][@bibr5-1534735415624138][@bibr6-1534735415624138][@bibr7-1534735415624138]-[@bibr8-1534735415624138]^; mitigating this symptom is a high priority and a clear unmet need. In this pilot study, we demonstrated successful recruitment and retention to a study of acupuncture for dyspnea in LC. There was a statistically and clinically significant improvement in dyspnea, as measured with both the NRS and CDS. At the time of follow-up, nearly 80% of patients reported some improvement in their dyspnea. Acupuncture was well tolerated, and there were no episodes of pneumothorax despite a significant rate of emphysema among patients with LC. In addition to improving dyspnea, acupuncture was also associated with improved fatigue and quality of life.

Although dyspnea is a debilitating symptom, with even mild symptoms leading to significant interruption of normal activities of daily living,^[@bibr26-1534735415624138]^ currently available therapies are inadequate. The current standard of care for dyspnea among patients with advanced cancer is low-dose opioids, which are associated with significant side effects.^[@bibr9-1534735415624138]^ Our study revealed an effect size for acupuncture that was similar to that previously reported for opioids,^[@bibr31-1534735415624138],[@bibr32-1534735415624138]^ with an improved side effect profile for acupuncture. This observation needs to be confirmed in a larger, randomized study.

Dyspnea has previously shown a strong correlation with quality of life and fatigue.^[@bibr33-1534735415624138],[@bibr34-1534735415624138]^ Indeed, for some patients with LC, fatigue and dyspnea represent the same clinical entity.^[@bibr26-1534735415624138]^ Thus, the effect seen in our study on quality of life and fatigue is not surprising. Interestingly, subjective dyspnea severity has historically exhibited poor correlation with expected objective factors predicting degraded lung function. For instance, dyspnea severity is not associated with the extent of LC surgery, and its correlation with pulmonary function tests has been inconsistent.^[@bibr5-1534735415624138],[@bibr35-1534735415624138]^ Therefore, it is not surprising that we were able to see an improvement in dyspnea severity without a change in objective pulmonary measurements. It should be noted, however, that all objective measurements exhibited a numerical improvement. Prior studies of acupuncture for other lung diseases have shown improvement in pulmonary function test measurements.^[@bibr36-1534735415624138],[@bibr37-1534735415624138]^ Our pilot study was not adequately powered to detect a significant improvement.

This study has a number of important limitations. First, the lack of a control group makes it impossible to rule out the possibility of a placebo effect or symptomatic improvement independent of the intervention itself. Whereas prior studies have raised the concern of a placebo response to acupuncture,^[@bibr38-1534735415624138]^ this seems to be mostly limited to sham acupuncture. Prior work by our group has indicated that response expectancy, a key component of the placebo effect, is not a predictor of response to true acupuncture.^[@bibr39-1534735415624138]^ Although we cannot exclude symptomatic improvement independent of the intervention, dyspnea and other symptoms generally worsen over time among patients with LC.^[@bibr2-1534735415624138],[@bibr40-1534735415624138]^ The presence of a significant improvement in dyspnea is, thus, notable. Next, our population was relatively heterogeneous, including patients with cured and active cancer who had received a variety of prior treatments. For instance, some patients became quite ill related to their disease and were unable to complete follow-up. Although this is certainly a limitation, it may reflect a more "real-world" application of acupuncture for dyspnea and would be expected to bias our study toward the null. Finally, our sample size in this pilot trial was small, which, when combined with the heterogeneous population, may limit generalizability of our findings. Our findings should be confirmed in a larger, randomized study.

In spite of these limitations, our study has notable strengths. Dyspnea is a major cause of symptomatic distress for patients with LC,^[@bibr4-1534735415624138],[@bibr8-1534735415624138]^ and currently available therapies for its treatment are inadequate and can have significant toxicities (eg, opioids).^[@bibr9-1534735415624138]^ Acupuncture was well tolerated by a group of patients with LC, and performing a trial in this population was feasible. This was the first trial to use the CDS in the context of a clinical trial, and it seemed to be responsive to change. In conclusion, acupuncture exhibited promising preliminary effects in the treatment of dyspnea. This benefit needs to be confirmed in a larger, randomized controlled study.
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